Biotech news
Europe
Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed. 22 April 2025
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis. 22 April 2025
Careers
The firm hired Brent Babcock as a partner in New York, bringing experience in cases involving biotechnology and medical devices. 22 April 2025
Europe
According to the Patent Index 2024, patent filings remained high in Europe last year “despite political and economic uncertainties” | Johnson & Johnson ranked among the top requesters of unitary patents. 8 April 2025
Careers
Combining USPTO work with a background in molecular biology, immunology, and plant biochemistry, the new counsel brings patent practitioner and examiner skills to the firm. 27 March 2025
Americas
Danish biotech prepares defence against allegations of trade secret misappropriation | AbbVie claims two former employees helped ProfoundBio use confidential tech to improve its cancer treatment pipeline ahead of Genmab acquisition. 25 March 2025
Europe
New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial molecular imaging products. 20 March 2025
Americas
Companies are transforming IP from a defensive tool into a revenue-generating powerhouse. Marisa Woutersen at the WIPR Summit 2025 hears trends in licensing, platform-based monetisation, and litigation funding. 18 March 2025
Americas
Complaint centres on AI-powered tools for cancer diagnostics | Tempus says its rival has a history of deliberately copying competitors’ technologies. 18 March 2025
Americas
As IP professionals wait for agency cutbacks to be felt down the chain, the advice is to stay informed, manage budgets wisely, and use a mix of protections to weather any disruption, finds Marisa Woutersen. 13 March 2025